In the BioHarmony Drug Report Database
Mipomersen
Kynamro (mipomersen) is an oligonucleotide pharmaceutical. Mipomersen was first approved as Kynamro on 2013-01-29. It is used to treat familial combined hyperlipidemia in the USA. Kynamro’s patents are valid until 2027-01-29 (FDA).
Trade Name
|
Kynamro |
|---|---|
Common Name
|
mipomersen |
ChEMBL ID
|
CHEMBL2219536 |
Indication
|
familial combined hyperlipidemia |
Drug Class
|
Antisense oligonucleotides |
Image (chem structure or protein)